NasdaqGM:SAGE

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system (CNS) disorders. More Details


Snowflake Analysis

Flawless balance sheet and undervalued.

Share Price & News

How has Sage Therapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: SAGE is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 8% a week.

Volatility Over Time: SAGE's weekly volatility (8%) has been stable over the past year.


Market Performance


7 Day Return

-9.4%

SAGE

-4.3%

US Biotechs

-0.4%

US Market


1 Year Return

60.1%

SAGE

24.2%

US Biotechs

36.2%

US Market

Return vs Industry: SAGE exceeded the US Biotechs industry which returned 24.2% over the past year.

Return vs Market: SAGE exceeded the US Market which returned 36.2% over the past year.


Shareholder returns

SAGEIndustryMarket
7 Day-9.4%-4.3%-0.4%
30 Day-2.4%-10.3%-2.3%
90 Day7.3%-0.8%5.0%
1 Year60.1%60.1%26.1%24.2%39.1%36.2%
3 Year-56.7%-56.7%12.0%6.3%48.4%39.0%
5 Year123.3%123.3%51.3%39.9%116.6%92.4%

Long-Term Price Volatility Vs. Market

How volatile is Sage Therapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Sage Therapeutics undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: SAGE ($76.98) is trading below our estimate of fair value ($436.71)

Significantly Below Fair Value: SAGE is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: SAGE is good value based on its PE Ratio (6.6x) compared to the US Biotechs industry average (21.3x).

PE vs Market: SAGE is good value based on its PE Ratio (6.6x) compared to the US market (21.5x).


Price to Earnings Growth Ratio

PEG Ratio: SAGE's earnings are forecast to decline next year, so we can't calculate its PEG ratio.


Price to Book Ratio

PB vs Industry: SAGE is good value based on its PB Ratio (2.2x) compared to the US Biotechs industry average (3.9x).


Next Steps

Future Growth

How is Sage Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 19 analysts?

-19.1%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: SAGE's earnings are forecast to decline over the next 3 years (-19.1% per year).

Earnings vs Market: SAGE's earnings are forecast to decline over the next 3 years (-19.1% per year).

High Growth Earnings: SAGE's earnings are forecast to decline over the next 3 years.

Revenue vs Market: SAGE's revenue is expected to decline over the next 3 years (-15.2% per year).

High Growth Revenue: SAGE's revenue is forecast to decline over the next 3 years (-15.2% per year).


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: SAGE is forecast to be unprofitable in 3 years.


Next Steps

Past Performance

How has Sage Therapeutics performed over the past 5 years?

-17.8%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: SAGE has high quality earnings.

Growing Profit Margin: SAGE became profitable in the past.


Past Earnings Growth Analysis

Earnings Trend: SAGE has become profitable over the past 5 years, growing earnings by -17.8% per year.

Accelerating Growth: SAGE has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: SAGE has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (-13.6%).


Return on Equity

High ROE: SAGE's Return on Equity (29.2%) is considered high.


Next Steps

Financial Health

How is Sage Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: SAGE's short term assets ($2.1B) exceed its short term liabilities ($67.2M).

Long Term Liabilities: SAGE's short term assets ($2.1B) exceed its long term liabilities ($19.7M).


Debt to Equity History and Analysis

Debt Level: SAGE is debt free.

Reducing Debt: SAGE has not had any debt for past 5 years.

Debt Coverage: SAGE has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: SAGE has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Next Steps

Dividend

What is Sage Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate SAGE's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate SAGE's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if SAGE's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if SAGE's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of SAGE's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

5.5yrs

Average management tenure


CEO

Barry Greene (57 yo)

0.25

Tenure

Mr. Barry E. Greene serves as President and Chief Executive Officer at Sage Therapeutics, Inc. since December 15, 2020 and its Director since October 1, 2020. He is a Director at BCLS Acquisition Corp. He ...


Leadership Team

NamePositionTenureCompensationOwnership
Kimi Iguchi
CFO & Treasurer8yrsUS$3.93m0.061%
$ 2.7m
Michael Cloonan
Chief Operating Officer0.83yrUS$4.95m0.0036%
$ 161.8k
Anne Cook
Senior VP5.5yrsUS$3.95m0.0030%
$ 135.3k
Jeffrey Jonas
Chief Innovation Officer7.58yrsUS$9.90m0.096%
$ 4.3m
Stephen Kanes
Chief Medical Officer7.67yrsUS$3.97m0.014%
$ 638.2k
Barry Greene
President0.25yrno datano data
Heinrich Schlieker
Senior Vice President of Technical Operations5.5yrsno datano data
Albert Robichaud
Chief Scientific Officer9.33yrsUS$3.67m0.23%
$ 10.5m
Matthew Calistri
Vice President of Investor Relations1.75yrsno datano data
Erin Lanciani
Senior Vice President of People & Organizational Strategyno datano datano data
Amy Schacterle
Senior Vice President of Global Regulatory Affairs & Policy3.92yrsno datano data
Jim Doherty
Chief Research Officer5.5yrsno datano data

5.5yrs

Average Tenure

57.5yo

Average Age

Experienced Management: SAGE's management team is seasoned and experienced (5.5 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Jeffrey Jonas
Chief Innovation Officer7.58yrsUS$9.90m0.096%
$ 4.3m
Barry Greene
President0.25yrno datano data
Kevin Starr
Independent Chairmanno dataUS$1.16m0.52%
$ 23.3m
Michael Cola
Independent Director6.5yrsUS$1.15m0%
$ 0
James Frates
Independent Director6.83yrsUS$1.14m0.0018%
$ 79.5k
Steven Paul
Founder & Independent Director9.5yrsUS$1.13m0.68%
$ 30.4m
David Farb
Member of Scientific Advisory Boardno datano datano data
Geno Germano
Independent Director4.67yrsUS$1.13m0%
$ 0
James Audia
Member of Scientific Advisory Boardno datano datano data
Christine Marx
Member of Scientific Advisory Boardno datano datano data
A. Morrow
Member of Scientific Advisory Boardno datano datano data
Stephen Moss
Member of Scientific Advisory Boardno datano datano data

6.7yrs

Average Tenure

59.5yo

Average Age

Experienced Board: SAGE's board of directors are considered experienced (6.7 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 12.5%.


Top Shareholders

Company Information

Sage Therapeutics, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Sage Therapeutics, Inc.
  • Ticker: SAGE
  • Exchange: NasdaqGM
  • Founded: 2010
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$4.494b
  • Shares outstanding: 58.38m
  • Website: https://www.sagerx.com

Number of Employees


Location

  • Sage Therapeutics, Inc.
  • 215 First Street
  • Cambridge
  • Massachusetts
  • 2142
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
SAGENasdaqGM (Nasdaq Global Market)YesCommon StockUSUSDJul 2014
SG7BST (Boerse-Stuttgart)YesCommon StockDEEURJul 2014
SG7DB (Deutsche Boerse AG)YesCommon StockDEEURJul 2014

Biography

Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system (CNS) disorders. Its lead product candidate is ZULRESSO, a proprietary intr...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/03/07 00:30
End of Day Share Price2021/03/05 00:00
Earnings2020/12/31
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.